What are the CDC guidelines for PrEP in HIV infection?

Updated: Jul 27, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

PrEP treatment guidelines include the following recommendations:

  • Acute and chronic HIV infection must be excluded by symptom history and HIV testing immediately before PrEP is prescribed; evidence level IA
  • Two medication regimens are approved by the FDA and recommended for PrEP with all the populations specified in the CDC guideline is daily TDF 300 mg coformulated with FTC 200 mg (Truvada) or the fixed-dose combination of FTC 200 mg plus TAF 25 mg (Descovy); evidence level IA
  • TDF alone has shown substantial efficacy and safety in trials with IDUs and heterosexually active adults and can be considered as an alternative regimen for these populations, but not for MSM, among whom its efficacy has not been studied; evidence level IC
  • Use of other ART medications for PrEP, either in place of or in addition to TDF/FTC (or TDF) or TAF/FTC is not recommended; evidence level IIIA
  • Oral PrEP for coitally-timed or other noncontinuous daily use is not recommended; evidence level IIIA

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!